SCHEMBL20575474

SCHEMBL20575474

Cc1cccc(N2C=C3CCCN3C2c2ccc3ncsc3c2)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 5/20 0.37
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
SYK P43405 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HSD11B1 P28845 2/20 0.32
PDE10A Q9Y233 1/20 0.32
PFKFB3 Q16875 2/20 0.31
CHRNA7 P36544 1/20 0.30
DPP4 P27487 1/20 0.30
DPP8 Q6V1X1 1/20 0.30
HTR3E A5X5Y0 1/20 0.30
HTR3B O95264 1/20 0.30
HTR3A P46098 1/20 0.30
HTR3D Q70Z44 1/20 0.30
HTR3C Q8WXA8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20575606 0.80 SLC6A2 (0.36) SLC6A2SLC6A4SLC6A3ALDH1A1LMNA
SCHEMBL20575637 0.80 NPC1 (0.36) SLC6A2SLC6A4SLC6A3ALDH1A1LMNA
SCHEMBL20575162 0.80 NPC1 (0.38) SLC6A2SLC6A4SLC6A3ALDH1A1LMNA
SCHEMBL20575188 0.78 SLC6A2 (0.34) TGFBR1SLC6A2SLC6A4SLC6A3ALDH1A1
SCHEMBL20575587 0.78 SLC6A2 (0.34) TGFBR1SLC6A2SLC6A4SLC6A3ALDH1A1
SCHEMBL20575589 0.78 TGFBR1 (0.35) TGFBR1SLC6A2SLC6A4SLC6A3ALDH1A1
SCHEMBL20575534 0.78 SLC6A4 (0.34) SLC6A2SLC6A4SLC6A3ALDH1A1LMNA
SCHEMBL20575191 0.78 SLC6A2 (0.34) SLC6A2SLC6A4SLC6A3ALDH1A1LMNA
SCHEMBL20575667 0.78 KDM1A (0.35) SLC6A2SLC6A4SLC6A3ALDH1A1LMNA
SCHEMBL20575561 0.77 KDM1A (0.35) TGFBR1SLC6A2SLC6A4SLC6A3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180346487-A1 Fused Imidazole Derivatives as TGF-Beta Inhibitors MIDCAP FINANCIAL TRUST 2018-12-06 US claimed
US-10696693-B2 Fused imidazole derivatives as TGF-beta inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2020-06-30 US disclosed
US-20180346487-A1 Fused Imidazole Derivatives as TGF-Beta Inhibitors MIDCAP FINANCIAL TRUST 2018-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10696693-B2 Fused imidazole derivatives as TGF-beta inhibitors TGFBR1, TGFBR2, SMAD3 TGFBR1 1/4885SLC6A2 3506/4885SLC6A4 3203/4885
US-20180346487-A1 Fused Imidazole Derivatives as TGF-Beta Inhibitors TGFBR1, TGFBR2, SMAD3 TGFBR1 1/4885SLC6A2 3506/4885SLC6A4 3203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.